var data={"title":"Pamidronate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pamidronate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6717?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pamidronate-drug-information\" class=\"drug drug_general\">see &quot;Pamidronate: Drug information&quot;</a> and <a href=\"topic.htm?path=pamidronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pamidronate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205912\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aredia;</li>\n      <li>Pamidronate Disodium;</li>\n      <li>Pamidronate Disodium Omega;</li>\n      <li>PMS-Pamidronate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060822\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hypercalcemia</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bisphosphonate Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21800858\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Osteogenesis imperfecta:</b> Limited data available: Full-term neonates, PNA &ge;14 days: IV: Initial: 0.25 mg/kg once on day 1, then 0.5 mg/kg/dose daily days 2 and 3 of the first cycle, then 0.5 mg/kg/dose once daily for 3 days for subsequent cycles; cycles are repeated every 2 months for a total yearly dose of 9 mg/kg (Rauch 2003; Zietlin 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060817\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pamidronate-drug-information\" class=\"drug drug_general\">see &quot;Pamidronate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Due to increased risk of nephrotoxicity, single doses should not exceed 90 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypercalcemia:</b> Limited data available: Children and Adolescents: Dosing based on several case reports and retrospective studies for treatment of hypercalcemia due to malignancy and/or immobility. Administer as a single infusion. Retreatment may be necessary if serum calcium does not return to normal or does not remain normal after initial treatment; reported interval for multiple doses is &ge;24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial treatment: IV: 0.5 to 1 mg/kg; maximum dose: 90 mg (Kerdudo 2005; Kutluk 1999; Lteif 1998; Young 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe, life-threatening: IV: 1.5 to 2 mg/kg; maximum dose: 90 mg; in one case report, a higher dose of 4 mg/kg was used to treat a serum calcium concentration of 18.9 mg/dL associated with bone metastases in a 4-year old child with non-Hodgkin lymphoma (Kerdudo 2005; Kutluk 1997; Kutluk 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteogenesis imperfecta:</b> Limited data available: <b>Note:</b> Reported dosing regimens variable (ie, weight-directed vs BSA-directed); duration of treatment has not been established; however, the most benefit has been shown to occur in the first 2 to 4 years of treatment (Rauch 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing (Rauch 2003; Zietlin 2003): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: IV: Initial: 0.25 mg/kg once on day 1, then 0.5 mg/kg/dose daily days 2 and 3 of the first cycle, then 0.5 mg/kg/dose once daily for 3 days for subsequent cycles; cycles are repeated every 2 months for a total yearly dose of 9 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 3 years: IV: Initial: 0.38 mg/kg once on day 1, then 0.75 mg/kg/dose daily days 2 and 3 of the first cycle, then 0.75 mg/kg/dose once daily for 3 days for subsequent cycles; cycles are repeated every 3 months for a total yearly dose of 9 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;3 years and Adolescents: IV: Initial: 0.5 mg/kg once on day 1, then 1 mg/kg/dose daily days 2 and 3 of the first cycle, then 1 mg/kg/dose once daily for 3 days for subsequent cycles; cycles are repeated every 4 months for a total yearly dose of 9 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\"> BSA-directed dosing: Infants, Children, and Adolescents: IV: Initial: 10 mg/<b>m<sup>2</sup></b>/dose once a month for 3 months, then increase to 20 mg/<b>m<sup>2</sup></b>/dose once a month for 3 months, then increase to 30 mg/<b>m<sup>2</sup></b>/dose once a month for subsequent doses; maximum dose: 40 mg/<b>m<sup>2</sup></b>/dose was used in six patients after 1-2 years due to skeletal pain and less bone mineral gain; improvements in mobility and vertebral height was noted in patients who received this regimen for 3 to 6 years (n=11, median age at initiation of therapy: 3.6 months, range: 3 to 13 months) (Astrom 2007); another study used the same dosing in 14 prepubescent patients with mild disease (Heino 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteopenia associated with cerebral palsy (nonambulatory):</b> Limited data available; dosing regimens variable: Children and Adolescents: IV: Initial: 1 mg/kg/dose daily for 3 days; administer every 3 to 4 months; minimum dose: 15 mg; maximum dose: 35 mg. Dosing based on two trials; the first included 14 pediatric patients (age range: 6 to 16 years, treatment group: n=7), and reported an increase in bone mineral density; therapy was used in combination with calcium and vitamin D supplementation (Henderson 2002). In the other trial (n=25, age range: 3 to 19 years), a decreased incidence of fractures was noted after 1 year of therapy (Bachrach 2010). A lower dose was used in a trial of 23 pediatric patients (age range: 4 to 17 years); the initial dose was 0.37 mg/kg on day 1, followed by 0.75 mg/kg on day 2, then  0.75 mg/kg/dose once daily for 2 days was used for subsequent cycles; cycles were repeated every 4 months for 1 year; maximum single dose: 45 mg (Plotkin 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypercalcemia of malignancy:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate cancer-related hypercalcemia (corrected serum calcium 12 to 13.5 mg/dL): 60-90 mg as a single dose over 2 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe cancer-related hypercalcemia (corrected serum calcium &gt;13.5 mg/dL): 90 mg as a single dose over 2 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Retreatment in patients who show an initial complete or partial response (allow at least 7 days to elapse prior to retreatment): May retreat at the same dose if serum calcium does not return to normal or does not remain normal after initial treatment   </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple myeloma, osteolytic bone lesions:</b> IV: 90 mg over 4 hours once  monthly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, osteolytic bone metastases:</b>  IV: 90 mg over 2 hours every 3 to 4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paget's disease, moderate to severe:</b> IV: 30 mg over 4 hours daily for 3 consecutive days (total dose = 90 mg); may retreat at initial dose if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline:</i> Patients with serum creatinine &gt;3 mg/dL were excluded from clinical trials; there are only limited pharmacokinetic data in patients with CrCl &lt;30 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's recommendations: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment of bone metastases: Use is not recommended in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Renal impairment in indications other than bone metastases: Use clinical judgment to determine if benefit outweighs risks. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following recommendations have been used by some clinicians: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Multiple myeloma: American Society of Clinical Oncology (ASCO) guidelines (Kyle 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Severe renal impairment (serum creatinine &gt;3 mg/dL <b>or</b> CrCl &lt;30 mL/minute) and extensive bone disease: 90 mg over 4 to 6 hours; however, a reduced initial dose should be considered if renal impairment was preexisting.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Albuminuria &gt;500 mg/24 hours (unexplained): Withhold dose until returns to baseline, then recheck every 3 to 4 weeks; consider reinitiating at a dose not to exceed 90 mg every 4 weeks and with a longer infusion time of at least 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>During therapy:</i> In patients with bone metastases, treatment should be withheld for deterioration in renal function (increase of serum creatinine &ge;0.5 mg/dL in patients with normal baseline or &ge;1 mg/dL in patients with abnormal baseline). Resumption of therapy may be considered when serum creatinine returns to within 10% of baseline. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh class A or B): No adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment (Child-Pugh class C):  There are no dosage adjustments provided in manufacturer's labeling; not studied.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205888\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as disodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg/10 mL (10 mL); 90 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as disodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg/10 mL (10 mL [DSC]); 6 mg/mL (10 mL); 90 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as disodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg (1 ea); 90 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205873\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060825\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Infusion rate varies by indication; longer infusion times (&gt;2 hours) may reduce the risk for renal toxicity, especially in patients with preexisting renal insufficiency. In adults, the manufacturer recommends infusing over 2 to 24 hours for hypercalcemia of malignancy, over 2 hours for osteolytic bone lesions with metastatic breast cancer, and over 4 hours for Paget's disease and for osteolytic bone lesions with multiple myeloma. In pediatric trials, infusion times were 4 hours for osteogenesis imperfecta, 3 to 4 hours for osteopenia from immobility, and 4 to 6 hours for hypercalcemia; a 24-hour infusion has also been used (Henderson 2002; Kerdudo 2005; Kutluk 1997; Lteif 1998; Rauch 2003; Young 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132758\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed-system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205905\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Powder for reconstitution: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). The reconstituted solution is stable for 24 hours stored under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). The diluted solution for infusion is stable in D5W or NS at room temperature for up to 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution for injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). The diluted solution for infusion is stable in D5W or NS at room temperature for up to 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060824\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderate or severe hypercalcemia associated with malignancy with or without bone metastases (in conjunction with adequate hydration); treatment of osteolytic bone lesions associated with multiple myeloma or metastatic breast cancer; treatment of moderate to severe Paget's disease of bone (All indications: FDA approved in adults); has also been used in the treatment of osteogenesis imperfecta and osteopenia in cerebral palsy patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205962\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aredia may be confused with Adriamycin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pamidronate may be confused with papaverine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205958\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation (hypercalcemia of malignancy), atrial flutter (hypercalcemia of malignancy), cardiac failure (hypercalcemia of malignancy), edema (hypercalcemia of malignancy), hypertension, syncope (hypercalcemia of malignancy), tachycardia (hypercalcemia of malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety (osteolytic bone metastases), drowsiness (hypercalcemia of malignancy), fatigue (more common in osteolytic bone metastases), headache, insomnia (more common in osteolytic bone metastases), pain, psychosis (hypercalcemia of malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypervolemia (hypercalcemia of malignancy), hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypothyroidism (hypercalcemia of malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (more common in osteolytic bone metastases), anorexia (more common in osteolytic bone metastases), constipation (hypercalcemia of malignancy), diarrhea (hypercalcemia of malignancy), dyspepsia (more common in osteolytic bone metastases), gastrointestinal hemorrhage (hypercalcemia of malignancy), nausea (more common in osteolytic bone metastases), stomatitis (hypercalcemia of malignancy) vomiting (more common in osteolytic bone metastases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Uremia (hypercalcemia of malignancy), urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (more common in osteolytic bone metastases), granulocytopenia (osteolytic bone metastases), leukopenia (hypercalcemia of malignancy), metastases (osteolytic bone metastases), neutropenia (hypercalcemia of malignancy), thrombocytopenia (hypercalcemia of malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis (hypercalcemia of malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Infusion site reaction (hypercalcemia of malignancy; includes erythema, induration, pain, and swelling)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (osteolytic bone metastases), arthropathy (Paget disease), back pain (Paget disease), myalgia (more common in osteolytic bone metastases), ostealgia, weakness (osteolytic bone metastases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine (osteolytic bone metastases; mild), renal insufficiency (osteolytic bone metastases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (osteolytic bone metastases), dyspnea (more common in osteolytic bone metastases), pleural effusion (osteolytic bone metastases), rales (hypercalcemia of malignancy), rhinitis (hypercalcemia of malignancy), sinusitis (osteolytic bone metastases), upper respiratory tract infection (more common in osteolytic bone metastases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (may be transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Adult respiratory distress syndrome, anaphylactic shock, angioedema, confusion, conjunctivitis, electrolyte disturbance, episcleritis, femur fracture (subtrochanteric and diaphyseal), flu-like symptoms, focal segmental glomerulosclerosis (including collapsing variant), glomerulopathy, hematuria, herpes simplex infection (reactivation), herpes zoster (reactivation), hyperkalemia, hypernatremia, hypersensitivity reaction, hypotension, interstitial pulmonary disease, iritis, local inflammation (orbital), malaise, mineral abnormalities, nephrotic syndrome, osteonecrosis (primarily of the jaw), paresthesia, pruritus, renal failure, renal tubular disease, scleritis, skin rash, tetany, uveitis, visual hallucination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205895\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pamidronate, other bisphosphonates, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205877\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures (after minimal or no trauma) have been reported. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures. Patients receiving long-term (&gt;3 to 5 years) bisphosphonate therapy may be at an increased risk. Consider discontinuing pamidronate in patients with a suspected femoral shaft fracture. Patients who present with thigh or groin pain in the absence of trauma should be evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Musculoskeletal pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte abnormalities: Use has been associated with asymptomatic electrolyte abnormalities (including hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia). Rare cases of symptomatic hypocalcemia, including tetany,  have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myelosuppression: Patients with preexisting anemia, leukopenia, or thrombocytopenia should be closely monitored during the first 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use and/or may be reported at a greater frequency based on tumor type (eg, advanced breast cancer, multiple myeloma). According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with monthly IV antiresorptive therapy compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years. The AAOMS suggests that if medically permissible, initiation of IV bisphosphonates for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiresorptive therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once IV bisphosphonate therapy is initiated for oncologic disease, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal deterioration: Single pamidronate doses should not exceed 90 mg. Initial or single doses have been associated with renal deterioration, progressing to renal failure and dialysis. Glomerulosclerosis (focal segmental) with or without nephrotic syndrome has also been reported. Longer infusion times (&gt;2 hours) may reduce the risk for renal toxicity, especially in patients with pre-existing renal insufficiency. Withhold pamidronate treatment (until renal function returns to baseline) in patients with evidence of renal deterioration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer (metastatic): The American Society of Clinical Oncology (ASCO) updated guidelines on the role of bone-modifying agents (BMAs) in the prevention and treatment of skeletal-related events for metastatic breast cancer patients (Van Poznak, 2011). The guidelines recommend initiating a BMA (denosumab, pamidronate, zoledronic acid) in patients with metastatic breast cancer to the bone. There is currently no literature indicating the superiority of one particular BMA. Optimal duration is not yet defined; however, the guidelines recommend continuing therapy until substantial decline in patient&rsquo;s performance status. The ASCO guidelines are in alignment with prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. BMAs are not the first-line therapy for pain. BMAs are to be used as adjunctive therapy for cancer-related bone pain associated with bone metastasis, demonstrating a modest pain control benefit. BMAs should be used in conjunction with agents such as NSAIDS, opioid and nonopioid analgesics, corticosteroids, radiation/surgery, and interventional procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia of malignancy (HCM): Adequate hydration is required during treatment (urine output ~2 L/day); avoid overhydration, especially in patients with heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoparathyroidism: Use caution with a history of thyroid surgery; patients may have relative hypoparathyroidism, predisposing them to pamidronate-related hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Patients with Bence-Jones proteinuria and dehydration should be adequately hydrated prior to therapy. The American Society of Clinical Oncology (ASCO) has also published guidelines on bisphosphonates use for prevention and treatment of bone disease in multiple myeloma (Kyle, 2007). Bisphosphonate (pamidronate or zoledronic acid) use is recommended in multiple myeloma patients with lytic bone destruction or compression spine fracture from osteopenia. Bisphosphonates may also be considered in patients with pain secondary to osteolytic disease, adjunct therapy to stabilize fractures or impending fractures, and for multiple myeloma patients with osteopenia but no radiographic evidence of lytic bone disease. Bisphosphonates are not recommended in patients with solitary plasmacytoma, smoldering (asymptomatic) or indolent myeloma, or monoclonal gammopathy of undetermined significance. The guidelines recommend monthly treatment for a period of 2 years. At that time, consider discontinuing in responsive and stable patients, and reinitiate if a new-onset skeletal-related event occurs. The ASCO guidelines are in alignment with the prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. According to the guidelines, in patients with extensive bone disease with existing severe renal disease (a serum creatinine &gt;3 mg/dL or CrCl &lt;30 mL/minute) pamidronate at a dose of 90 mg over 4 to 6 hours should be used (unless preexisting renal disease in which case a reduced initial dose should be considered). Monitor for albuminuria every 3 to 6 months; in patients with unexplained albuminuria &gt;500 mg/24 hours, withhold the dose until level returns to baseline, then recheck every 3 to 4 weeks. Pamidronate may be reinitiated at a dose not to exceed 90 mg every 4 weeks with a longer infusion time of at least 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Patients with serum creatinine &gt;3 mg/dL were not studied in clinical trials; limited data are available in patients with CrCl &lt;30 mL/minute. Evaluate serum creatinine prior to each treatment. For the treatment of bone metastases, use is not recommended in patients with severe renal impairment. With indications other than bone metastases, use clinical judgment to determine if benefits outweigh potential risks in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26038952\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Maintain adequate hydration with therapy (pediatric patients: 2 to 3 L/m<sup>2</sup> [Kerdudo, 2005]) and urinary output during treatment; use with caution with other potentially nephrotoxic drugs. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Bisphosphonate therapy may not be appropriate for patients with mild osteogenesis imperfect; risk:benefit has not been established. Potential adverse effects in growing children include infusion reactions and effects on bone growth. Influenza-like reactions are common after the first dose occurring at 12 to 36 hours after the infusion and may include fever, rash, and vomiting; treatment with standard antipyretic therapy is usually adequate and symptoms do not generally recur after later doses. Increased height has been reported and theoretical effects of diminishing bone remodeling in a growing child may result in bone malformation or delayed recovery after fractures (Rauch, 2004). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299814\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205882\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12673&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: May enhance the nephrotoxic effect of Pamidronate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205884\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205897\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic, 2008; Stathopoulos, 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic, 2008; Levy, 2009; Stathopoulos, 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla, 2010; Pereira, 2012;  Stathopoulos, 2011). Because hypocalcemia has been described following <i>in utero</i> bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic, 2008; Stathopoulos, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060821\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor serum creatinine prior to each dose; monitor serum calcium, phosphate, potassium, and magnesium; monitor for hypocalcemia for at least 2 weeks after therapy; patients with pre-existing anemia, leukopenia, or thrombocytopenia should have hemoglobin, hematocrit, and CBC with differential monitored closely, particularly in the first 2 weeks following treatment; dental exam and preventative dentistry prior to therapy for patients at risk for osteonecrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional indication-specific monitoring:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple myeloma: Urine albumin every 3-6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteogenesis imperfecta: In pediatric trials, motor milestones, ambulation assessment, total body length, sitting height, and arm span were recorded every 6 months. Bone density was measured every 6 months. Conventional x-rays were obtained once yearly (Heino, 2011). Urinary excretion of calcium, alkaline phosphatase, and other bone-related chemistries were also monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteopenia associated with cerebral palsy: In pediatric trials, bone mineral density, number and location of fractures, conventional x-rays, serum vitamin D concentrations, alkaline phosphatase, and other bone related chemistries were monitored (Bachrach, 2010; Henderson, 2002; Plotkin, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Paget's disease: Monitor serum alkaline phosphatase and urinary hydroxyproline excretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205876\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitrogen-containing bisphosphonate; inhibits bone resorption and decreases mineralization by disrupting osteoclast activity (Gralow 2009; Rogers 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205894\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypercalcemia of malignancy (HCM): Reduction of albumin-corrected serum calcium: Children: ~48 hours (Kerdudo 2005); Adults: &le;24 hours for decrease in albumin-corrected serum calcium; maximum effect: &le;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paget disease: ~1 month for &ge;50% decrease in serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: Hypercalcemia of malignancy: &le;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: HCM: 7 to 14 days; Paget disease: 1 to 372 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Poorly from the GI tract </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 38% to 70% over 120 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Not metabolized </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 28 &plusmn; 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Biphasic; urine (30% to 62% as unchanged drug; lower in patients with renal dysfunction) within 120 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323599\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pamidronate Disodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (10 mL): $33.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pamidronate Disodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $111.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (1): $67.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205898\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aminomux (AR, PY, UY, VE);</li>\n      <li>Aredia (AE, AT, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Biodronate (LK);</li>\n      <li>Pamidria (LB);</li>\n      <li>Pamidrom (BR);</li>\n      <li>Pamidron (JO);</li>\n      <li>Pamisol (AU, MX, MY, NZ, SG, TW);</li>\n      <li>Pamitor (HR, TR);</li>\n      <li>Panolin (KR);</li>\n      <li>Panorin (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Astr&ouml;m E, Jorulf H, S&ouml;derh&auml;ll S. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. <i>Arch Dis Child</i>. 2007; 92(4):332-3388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/17114205/pubmed\" target=\"_blank\" id=\"17114205\">17114205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auron A, Tal L, Srivastava T, et.al.  Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates.<i> Pediatric Nephrology</i>. 2009; 24:613-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/18839218/pubmed\" target=\"_blank\" id=\"18839218\">18839218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bachrach SJ, Kecskemethy HH, Harcke HT, et al. Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. <i>Dev Med Child Neurol</i>. 2010;52(9):837-842.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/20573180/pubmed\" target=\"_blank\" id=\"20573180\">20573180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glorieux FH, Bishop NH, Plotkin H, et al, &ldquo;Cyclic Administration of Pamidronate in Children With Severe Osteogenesis Imperfecta,&rdquo; <i>N Engl J Med</i>, 1998, 339(14):947-52. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/9753709/pubmed\" target=\"_blank\" id=\"9753709\">9753709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heino T, Astrom E, Laurencikas E, et al. Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients. <i>Horm Res Paediatr</i>. 2011;75:354-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/21304249/pubmed\" target=\"_blank\" id=\"21304249\">21304249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henderson RC, Lark RK, Kecskemethy HH, et al, &ldquo;Bisphosphonates to Treat Osteopenia in Children With Quadriplegic Cerebral Palsy: A Randomized, Placebo-Controlled Clinical Trial,&rdquo; <i>J Pediatr</i>, 2002, 141(5):644-51. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/12410192/pubmed\" target=\"_blank\" id=\"12410192\">12410192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerdudo C, Aerts I, Fattet S, et al. Hypercalcemia and childhood cancer: a 7-year experience. <i>J Pediatr Hematol Oncol</i>. 2005;27(1):23-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/15654274/pubmed\" target=\"_blank\" id=\"15654274\">15654274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kutluk MT, Hazar V, Akyuz C, et.al. Childhood cancer and hypercalcemia: report of a case treated with pamidronate. <i>Journal of Pediatrics</i>. 1997;130(5):828-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/9152297/pubmed\" target=\"_blank\" id=\"9152297\">9152297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kutluk MT. Use of bisphosphonates in hypercalcemia associated with childhood cancer. <i>Journal of Clinical Oncology</i>. 1999;17(6):1960.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/10561239/pubmed\" target=\"_blank\" id=\"10561239\">10561239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. <i>J Clin Oncol</i>. 2007;25(17):2464-2472. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/17515569/pubmed\" target=\"_blank\" id=\"17515569\">17515569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lteif AN and Zimmerman D, &ldquo;Bisphosphonates for Treatment of Childhood Hypercalcemia,&rdquo; <i>Pediatrics</i>, 1998, 102(4 Pt 1):990-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/9755274/pubmed\" target=\"_blank\" id=\"9755274\">9755274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network (NCCN), &ldquo;Clinical Practice Guidelines in Oncology: Multiple Myeloma,&rdquo; Version 2.2014. Available at  http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>,  2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plotkin H, Coughlin S,  Kreikemeier R, et al. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. <i>Dev Med Child Neurol</i>. 2006;48(9):709-712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/16904014/pubmed\" target=\"_blank\" id=\"16904014\">16904014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. <i>J Clin Endocrinol Metab</i>. 2000;85:1846-1850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/10843163/pubmed\" target=\"_blank\" id=\"10843163\">10843163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rauch F, Glorieux FH. Osteogenesis imperfecta. <i>Lancet</i>. 2004;363(9418):1377-1385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/15110498/pubmed\" target=\"_blank\" id=\"15110498\">15110498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rauch F, Plotkin H, Travers R, et al. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. <i>J Clin Endocrinol Metab</i>. 2003;88(3):986-992.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/12629073/pubmed\" target=\"_blank\" id=\"12629073\">12629073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.<i> J Clin Endocrinol Metab</i>. 2006;91(2):511-516.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/16291701/pubmed\" target=\"_blank\" id=\"16291701\">16291701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.<i> J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/25234529 /pubmed\" target=\"_blank\" id=\"25234529 \">25234529 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siminoski K, Fitzgerald AA, Flesch G, et al, &quot;Intravenous Pamidronate for Treatment of Reflex Sympathetic Dystrophy During Breast Feeding,&quot;<i>J Bone Miner Res</i>, 2000, 15(10):2052-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/11028460/pubmed\" target=\"_blank\" id=\"11028460\">11028460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. <i>J Clin Oncol</i>. 2011;29(9):1221-7<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/21343561/pubmed\" target=\"_blank\" id=\"21343561\">21343561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.<i> Med Pediatr Oncol</i>. 1998;30(2):117-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/9403021/pubmed\" target=\"_blank\" id=\"9403021\">9403021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitlin L, Rauch F, Plotkin H, et al. Height and weight  development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfect types I, III and IV. <i>Pediatrics</i>. 2003;111:1030&ndash;1036.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-pediatric-drug-information/abstract-text/12728084/pubmed\" target=\"_blank\" id=\"12728084\">12728084</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12673 Version 136.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F205912\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060822\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F21800858\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060817\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F205888\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F205873\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060825\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132758\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F205905\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060824\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F205962\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F205958\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F205895\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F205877\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26038952\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299814\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F205882\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F205884\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F205897\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060821\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F205876\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F205894\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323599\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F205898\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12673|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pamidronate-drug-information\" class=\"drug drug_general\">Pamidronate: Drug information</a></li><li><a href=\"topic.htm?path=pamidronate-patient-drug-information\" class=\"drug drug_patient\">Pamidronate: Patient drug information</a></li></ul></div></div>","javascript":null}